BACKGROUND AND AIM: Pegylated interferon-α (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-α2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-α2A (180µg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA <351 IU/mL and hepatitis B e antigen (HBeAg) seroconversion. RESULTS: Sixty three HBeAg positive patients were identified (65% male, 80% born in Asia, 84% with viral loads > 6log IU/mL, 9.5% advanced fibrosis). Six months after therapy 46% achieved normalization of ALT, 16% had viral loads < 351 IU/mL and 32% achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75% male, 86% born in Asia, 48% had viral loads > 6log IU/mL, 24% advanced fibrosis). Six months post-treatment, 55% and 36% maintained a normalized ALT and HBV DNA < 351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75% of patients over 2 years of follow up. 6.5% of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.
BACKGROUND AND AIM: Pegylated interferon-α (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-α2A in CHB patients in a clinical setting. METHODS:Chronic hepatitis Bpatients treated with PEG-IFN-α2A (180µg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA <351 IU/mL and hepatitis B e antigen (HBeAg) seroconversion. RESULTS: Sixty three HBeAg positive patients were identified (65% male, 80% born in Asia, 84% with viral loads > 6log IU/mL, 9.5% advanced fibrosis). Six months after therapy 46% achieved normalization of ALT, 16% had viral loads < 351 IU/mL and 32% achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75% male, 86% born in Asia, 48% had viral loads > 6log IU/mL, 24% advanced fibrosis). Six months post-treatment, 55% and 36% maintained a normalized ALT and HBV DNA < 351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75% of patients over 2 years of follow up. 6.5% of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.
Authors: Monica C Robotin; Melanie Q Kansil; Mamta Porwal; Andrew G Penman; Jacob George Journal: Bull World Health Organ Date: 2014-02-04 Impact factor: 9.408
Authors: He Bin Fan; Ya Bin Guo; You Fu Zhu; An Shen Chen; Mu Xiu Zhou; Zhi Li; Li Tong Xu; Xiao Ju Ma; Fu Ming Yan Journal: Hepat Mon Date: 2012-05-30 Impact factor: 0.660
Authors: Young Eun Chon; Dong Joon Kim; Sang Gyune Kim; In Hee Kim; Si Hyun Bae; Seong Gyu Hwang; Jeong Heo; Jeong Won Jang; Byung Seok Lee; Hyung Joon Kim; Dae Won Jun; Kang Mo Kim; Woo Jin Chung; Moon Seok Choi; Jae Young Jang; Hyung Joon Yim; Won Young Tak; Ki Tae Yoon; Jun Yong Park; Kwang-Hyub Han; Ki Tae Suk; Hyun Woong Lee; Byoung Kuk Jang; Sang Hoon Ahn Journal: Medicine (Baltimore) Date: 2016-04 Impact factor: 1.889
Authors: Sylvia Drazilova; Martin Janicko; Pavol Kristian; Ivan Schreter; Branislav Kucinsky; Marek Kozlej; Ivana Hockickova; Peter Jarcuska Journal: Gastroenterol Res Pract Date: 2015-12-29 Impact factor: 2.260
Authors: Jung Hyun Kwon; Young Seok Kim; Sang Gyune Kim; Jeong Won Jang; Tae Hun Kim; Young Kul Jung; Oh Sang Kwon Journal: Gut Liver Date: 2013-02-07 Impact factor: 4.519